|
|
Article: Synageva BioPharma Announces Completion of $45 Million Financing with New $12 Million Investment, Addition of New Leaf Venture Partners to Investor Group, and Expansion of Senior Leadership Team.(Company overview)
- Article from:
- Biotech Week
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Synageva BioPharma Corp., a privately held biopharmaceutical company, announced that it has completed the final closing on a $45 million financing that began earlier this year. This final closing, which adds $12 million to the $33 million investment announced in May, includes existing investors as well as new investor New Leaf Venture Partners (NLV), based in New York City and Menlo Park, CA. As part of the financing, Srini Akkaraju, M.D., Ph.D., Managing Director at NLV, will join Synageva's Board of Directors. Synageva also announced the expansion of its senior leadership team with several key appointments (see also Synageva BioPharma Corp.).
"This $45 million ...
Related newspaper, magazine, and journal articles:
|